The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Tara Yates joins Wistar Institute as director of communications

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

TARA YATES was named director of communications of the Wistar Institute.

Yates comes to Wistar from Roswell Park Cancer Institute, where she was director of public affairs in the marketing department. While there, she led the public affairs team and managed internal, external and crisis communications, media relations, and web content for the comprehensive cancer center.

Yates also serves as vice-chair of the Public Affairs and Marketing Network, a professional organization of academically based comprehensive, clinical, basic and consortium cancer centers. PAMN works in close association with the NCI’s Office of Media Relations and Public Affairs to further public awareness of cancer research, prevention, detection and treatment.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account